Assertio Holdings to be Acquired by Zydus Worldwide DMCC for $23.50/Share in All-Cash Deal
ASRT has more than doubled off its 52-week low of $8.61.
Summary
Assertio Holdings has entered into a definitive agreement to be acquired by Zydus Worldwide DMCC for $23.50 per share in an all-cash tender offer, replacing a previous, lower offer from Garda Therapeutics.
Key Events · M&A and Partnerships · ASRT
-
Definitive Merger Agreement Signed
Assertio Holdings, Inc. has entered into an Agreement and Plan of Merger with Zydus Worldwide DMCC and Zara Merger Sub Inc. for an all-cash acquisition at $23.50 per share. The Board unanimously approved and recommended the offer.
-
Termination of Prior Acquisition Agreement
The company terminated its Amended and Restated Agreement and Plan of Merger with Garda Therapeutics, Inc., as the Zydus offer was deemed a 'Superior Proposal.' Zydus paid Garda a termination fee of $5,810,000 on Assertio's behalf.
-
Significant Premium Offered
The $23.50 per share offer represents a 30.6% premium to the original $18.00 per share Garda offer (April 8, 2026), a 7.8% premium to the amended $21.80 per share Garda offer (May 4, 2026), and a 75.8% premium to the unaffected closing stock price on March 20, 2026.
-
Convertible Notes Tender Offer
Assertio is required to make an offer and consent solicitation to purchase its $40,000,000 aggregate principal amount of 6.50% Convertible Notes due 2027 at 100% of the principal amount plus accrued interest, contingent on the merger's 'Fundamental Change'.
Analysis · ASRT · Life Sciences
This 8-K announces a definitive agreement for Assertio Holdings to be acquired by Zydus Worldwide DMCC for $23.50 per share in an all-cash tender offer. This is a critical, thesis-altering event for shareholders, as it represents a significant premium over the company's recent trading price and a substantial increase from a previously announced, lower acquisition offer by Garda Therapeutics. The termination of the prior Garda agreement and the payment of its termination fee by Zydus underscore the certainty of this new, higher-value transaction.
At the time of this filing, ASRT was trading at $23.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $145.7M. The 52-week trading range was $8.61 to $22.59. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.